TABLE 4.
Comparison of pharmacokinetic parameters and clinical efficacy (improvement of clinical signs and symptoms) by the most common infected sites.
| Infected site | PK parameters | Improved | Not improved | P value |
|---|---|---|---|---|
| Overall | Responding, n (%) | 100 (92.6) | 8 (7.4) | |
| Cmin,ss (mg/L),Median (IQR) | 1.50 (1.50, 5.75) | 1.50 (1.50, 4.92) | 0.8206 | |
| Cmin,ss (mg/L),Median (IQR) | 21.50 (16.89, 27.12) | 26.02 (22.01, 28.67) | 0.1146 | |
| AUC0–24, (hr*mg/L), median (IQR) | 217.5 (172.87, 286.34) | 212.6 (204.20, 314.50) | 0.4082 | |
| Bloodstream | Responding, n (%) | 49 (96.1) | 2 (3.9) | |
| Cmin,ss (mg/L),Median (IQR) | 1.50 (1.50, 5.95) | 1.50 | 0.2650 | |
| Cmax,ss (mg/L),Median (IQR) | 23.32 (17.20, 26.57) | 26.02 | 0.3693 | |
| AUC0–24, (hr*mg/L), median (IQR) | 215.9 (172.33, 305.85) | 225.0 | >0.9999 | |
| Pulmonary | Responding, n (%) | 27 (90.0) | 3 (10.0) | |
| Cmin,ss (mg/L),Median (IQR) | 3.02 (1.50, 6.17) | 3.32 | 0.8553 | |
| Cmax,ss (mg/L),Median (IQR) | 20.24 (16.24, 28.07) | 22.60 | 0.6783 | |
| AUC0–24, (hr*mg/L), median (IQR) | 219.2 (183.44, 266.38) | 213.1 | 0.5802 | |
| Urinary tract | Responding, n (%) | 16 (94.1) | 1 (5.9) | |
| Cmin,ss (mg/L),Median (IQR) | 1.50 (1.50, 5.99) | 1.50 | 0.4930 | |
| Cmax,ss (mg/L),Median (IQR) | 22.08 (15.80, 25.63) | 29.18 | 0.1846 | |
| AUC0–24, (hr*mg/L), median (IQR) | 196.2 (145.03, 287.92) | 212.1 | 0.9187 | |
| Central nerve system | Responding, n (%) | 10 (90.9) | 1 (9.1) | |
| Cmin,ss (mg/L),Median (IQR) | 4.77 (1.50, 10.58) | 1.50 | 0.3315 | |
| Cmax,ss (mg/L),Median (IQR) | 28.11 (24.75, 30.66) | 21.41 | 0.4292 | |
| AUC0–24, (hr*mg/L), median (IQR) | 303.3 (204.97, 386.18) | 200.1 | 0.4292 | |
| Endocarditis | Responding, n (%) | 6 (100.0) | 0 (0.0) | |
| Cmin,ss (mg/L),Median (IQR) | 1.50 (1.50, 3.63) | |||
| Cmax,ss (mg/L),Median (IQR) | 21.50 (17.20, 23.70) | |||
| AUC0–24, (hr*mg/L), median (IQR) | 213.4 (195.3, 239.1) |
Cmin, ss: trough concentration at steady state; Cmax, ss: peak concentration at steady state; AUC0–24: 0–24 h area under the curve; AUC0–24/MIC: the area under the curve to minimum inhibitory concentration ratio; IQR: interquartile range.
Data are presented as the median (IQR) or n (%); IQRs were not reported for n < 5.